Zhaoke Ophthalmology Limited (HKG:6622)

Market Cap	1.60B +38.6%
Revenue (ttm)	35.58M -53.9%
Net Income	-232.56M
EPS	-0.43
Shares Out	548.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	561,000
Average Volume	579,053
Open	2.930
Previous Close	2.930
Day's Range	2.910 - 3.020
52-Week Range	1.300 - 4.600
Beta	1.21
RSI	34.72
Earnings Date	Mar 25, 2026

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 270
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6622

Financial Performance

In 2025, Zhaoke Ophthalmology's revenue was 31.97 million, a decrease of -53.88% compared to the previous year's 69.32 million. Losses were -208.98 million, -12.00% less than in 2024.

Financial numbers in CNY